Clinical Evidence
Peer-reviewed research supports the advanced elastography systems we supply, with published data on accuracy and reliability in liver fibrosis assessment.
Peer-Reviewed Research
Key Studies
FibroTouch / iLivTouch in NAFLD and Comparative TE Literature
Multiple peer-reviewed sources (Various) • See primary publications and reviews
Published work reports FibroTouch NAFLD cohort measurement success around 96.5% in a large study. AUROC for ≥F2 fibrosis varies by study (commonly roughly 0.71–0.89); higher AUROC values (including ~0.94–0.96) align with advanced fibrosis/cirrhosis thresholds (≥F3–F4) in several cohorts. Obesity, narrow intercostal space, and ascites can limit reliability for any elastography modality.
Key Findings
- ~96.5% measurement success in large published NAFLD FibroTouch cohort
- AUROC for ≥F2 depends on population; ~0.95 values align with ≥F3–F4 in published data
- Compare FibroScan M vs XL probes when interpreting high-BMI performance
Comparative Failure Rates: VCTE vs 2D Shear Wave Elastography in Chronic Liver Disease
Hepatology and Radiology journals (2022–2024) • Sjöman et al. and related cohort studies
Comparative studies in chronic liver disease populations report VCTE (FibroScan) failure rates of approximately 11.6% vs 5.16% for guided elastography. In cases where VCTE returned no valid result, guided elastography provided a valid measurement in approximately 61% of those patients. Failure rates are substantially higher in patients with BMI >30 using the standard M probe.
Key Findings
- VCTE failure rate ~11.6% vs guided TE ~5.16% in CLD populations
- Guided TE rescues ~61% of cases VCTE could not complete
- Guided acquisition addresses the root cause of failure: inability to visualise probe placement
Clinical Guidelines
Supported by Leading Bodies
EASL
European Association for the Study of the Liver
Liver elastography is recommended as a first-line assessment for liver fibrosis in patients with chronic liver disease.
AASLD
American Association for the Study of Liver Diseases
Non-invasive tests including elastography should be used for initial fibrosis assessment, reserving biopsy for indeterminate cases.
GESA
Gastroenterological Society of Australia
Elastography-based assessment is recommended for MAFLD staging and monitoring in the Australian clinical context.
See the evidence firsthand
Schedule a demonstration to see supplied guided elastography accuracy and reliability in action.